Global Multiple Myeloma Drug Treatment Market Thoroughly Discussed in New Visiongain Report Now Available at

05 Nov 2012 • by Natalie Aster

LONDON – Multiple myeloma is a relatively widespread disease. In the USA alone, over 19,000 people are diagnosed with it each year. In 2012, almost 22,000 new cases were discovered and around 11,000 deaths took place in the country. The drug treatment enables to slow the multiple myeloma’s development or even stop it. Bortezomib, Thalomid and Lenalidomide are amid the most common drugs used for treatment of the disease. Besides, pharmaceutical companies permanently work on new medicines. For instance, Plitidepsin is amid new drugs currently undergoing testing.

New research report “World Multiple Myeloma Drug Treatment Market 2012-2022” elaborated by Visiongain provides a deep insight into the global market for multiple myeloma. The study offers a comprehensive overview of the market, discussion of past and current market trends, leading treatments and R&D pipeline. Qualitative analysis of the market for multiple myeloma, study of market segments, its drivers and restraints, data on revenues, companies’ assessment and future opportunities are also available in the report.

Report Details:

World Multiple Myeloma Drug Treatment Market 2012-2022
Published: September, 2012
Pages: 136
Price: US$ 2.739,00

More Cutting-Edge Research Reports by Visiongain are Available:

More new market research reports by the publisher can be found at Visiongain page.


MarketPublishers, Ltd.
Tanya Rezler
Tel: +44 208 144 6009
Fax: +44 207 900 3970